Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

PDI Seeks Deals For “Immediate Leverage”; Evista Could Contribute In 2003

  • News

Executive Summary

PDI expects to sign fee-for-services deals shortly to "create immediate leverage," CEO Charles Saldarini said during an Aug. 13 earnings call

You may also be interested in...



PDI Evista Lessons Learned: Firm Focuses On Smaller Contracts, No Baselines

PDI will focus on smaller contract sales opportunities in the 50-representative range following termination of the Evista promotion deal with Lilly, CEO Charles Saldarini said on a conference call Nov. 12

PDI Evista Lessons Learned: Firm Focuses On Smaller Contracts, No Baselines

PDI will focus on smaller contract sales opportunities in the 50-representative range following termination of the Evista promotion deal with Lilly, CEO Charles Saldarini said on a conference call Nov. 12

Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review

Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention

Table

View full table

Tags:
Latest Headlines

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

See All
UsernamePublicRestriction

Register

PS040345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By